Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on whether a checkpoint inhibitor should be prescribed to newly diagnosed lung cancer patients that have a PD-L1 expression that is less than 1%

Published: 16 April 2018

Recent Videos: Lung (includes NSCLC, SCLC, Mesothelioma)

video

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, clarifies how physicians should use the PD-L1 biomarker when ...

video

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, discusses stratifying newly diagnosed lung cancer patients with the ...

video

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on whether a checkpoint inhibitor should be prescribed to ...

video

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, discusses combinations and the treatment of lung cancer

video

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on how the recent National Coverage Determination for Next ...

video

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, describes how immunotherapies should be integrated into the treatment of ...

video

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, speculates on the future of immunotherapy combinations when treating small ...

video

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, elaborates on the challenges associated with biomarkers when treating small ...

video

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

Dr. Kim, Medical Oncologists, Levine Cancer Institute, shares how he is using the PD-L1 biomarker to help determine which patients ...

video

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

Dr. Simon, Professor of Medicine and Oncology, MD Anderson Cancer Center, describes the clinical studies presented at ASCO 2017 that ...

Related Videos

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Ted Okon, MBA, offers his interpretation of the Practice Impact Report released at COA 2018

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Robert Rifkin, MD, tells us about biosimilar pricing and reimbursement

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Rebecca A. Kirch, JD, on factors that should be considered before starting a palliative care program

video-image

Rebecca A. Kirch, JD, discusses the impact of high quality palliative care programs

video-image

Ray Page, DO, PhD, shares results of a recent study on bundled payments as an APM

video-image

Ray Page, DO, PhD, regarding bundled payments as a viable option for an APM for community oncology

video-image

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Miriam Atkins, MD, considers what COA is doing to educate patients on their cancer care

video-image

Michael Kolodziej, MD, FACP, on the legislative issues most salient to community oncologists today

video-image

Michael Kolodziej, MD, FACP, considers how the move from volume to value impacts community oncology

video-image

Mark Fendrick, MD, on cost containment strategies that work best in value-based insurance design

video-image

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Michael Diaz, MD, shares what COA is doing to educate cancer care patients

video-image

Michael Diaz, MD, tells us about the goals of the patient initiative on Capital Hill at COA 2018

video-image

Kathy Oubre on how lobbying has helped influence the community oncology agenda

video-image

Kathy Oubre outlines some of the lobbying tactics that community oncology practices should adopt

video-image

Kathy Oubre explains why it’s important for community oncology practices to participate in lobbying

video-image

Jonathan E. Levitt, Esq. explains why oncology practices should be aware of co-pay aggregators

video-image

Jonathan E. Levitt, Esq. on the importance of PBM transparency

video-image

Jonathan E. Levitt, Esq. discusses the problems that exist between PBMs and oncology providers

video-image

Jonathan E. Levitt, Esq. provides an update on the oncology landscape from a legal perspective

video-image

Jeff Mortier explains what can be done to encourage PBM transparency

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Jeff Mortier discusses some of the issues presented at Hill Day during COA 2018

video-image

James Hambrick, MD, on how real world evidence can be used by practicing oncologists

video-image

James Hambrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hambrick, MD, regarding the value of real world evidence data

video-image

Fred Schnell, MD, compares OCM 2.0 and OCM 1.0

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Fred Schnell, MD, considers why practice transformation is often difficult in oncology

video-image

Debra Patt, MD, MPH, MBA, regarding advances in next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, considers reimbursement & coverage of CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on what community oncologists should know before prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, explains the benefits & challenges associated with prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, analyzes the logistics associated with CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on CMS’s National Coverage Determination & next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, regarding the reliability of next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, on the progress being made in next-generation sequencing

video-image

Bud Pierce, MD, describes how Oregon Oncology Specialists has evolved

video-image

Bud Pierce, MD, explains what his practice is doing to alleviate financial toxicity

video-image

Bud Pierce, MD, regarding the doctor-patient relationship in today’s oncology landscape

video-image

Brian DeLashmutt considers cost of care in hospital-based & community oncology settings

video-image

Brian DeLashmutt shares details of his own cancer care experience

video-image

Houston Holmes, MD, MBA, FACP, provides perspective on reimbursement & coverage of CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on what community oncologists should know about prescribing CAR-Ts

video-image

Houston Holmes, MD, MBA, FACP, regarding the benefits & challenges of prescribing CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on the logistics associated with CAR-T therapies

video-image

Suanne Gersdorf, FACHE, MSB, on the impact of value-based care and easing financial toxicity

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Suanne Gersdorf, FACHE, MSB, considers how EHR data can be used to improve outcomes

video-image

Suanne Gersdorf, FACHE, MSB, on how oncology practices have become more efficient in utilizing APNs

video-image

Suanne Gersdorf, FACHE, MSB, regarding the importance of embracing APNs

video-image

Harry “Mac” Barnes, MD, explains the benefits of training advanced practitioners

video-image

Harry “Mac” Barnes, MD, elaborates on the role of advanced care providers in cancer patient care

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents

video-image

Ray Bailey explains how he works with payers to dispense oral cancer agents to patients

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system

video-image

Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting

video-image

Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care

video-image

Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system

video-image

Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data

video-image

Bobbi Buell offers advice to practices on how to guarantee good coding

video-image

Bobbi Buell on the implications of mistakes in coding

video-image

Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology

video-image

Bruce Feinberg, DO, shares his special interest in value-based care

video-image

Bruce Feinberg, DO, comments on site of care and its impact on cancer economics

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, reflects on how his practice manages the transition to value-based care

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Edward Li considers how comfortable medical oncologists and patients should be with biosimilars

video-image

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

video-image

Edward Li outlines the legal challenges surrounding biosimilars and market entry

video-image

Edward Li on the status of the biosimilars regulatory pathway

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive

video-image

Ben Jones on the hot policy topics impacting the delivery of quality cancer care

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

video-image

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

video-image

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges

video-image

James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow

video-image

James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care

video-image

Matt Farber describes how specialty pharmacies differ

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

Skip Burris, MD, offers his opinion on searching for rare mutations

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Bobbi Buell explains how practices can avoid the most common mistakes in billing

video-image

Skip Burris, MD, offers his opinion on molecular profiling patients

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

Brad Prechtl explains how “shared savings” works between FCS and a local payer

video-image

Brad Prechtl on the keys to success for Florida Cancer Specialists

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

William Harwin, MD, describes the shift from fee for service to value-based care

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA

video-image

Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings

video-image

Ricky Newton provides an example of how a PBM is impacting cancer patient care

video-image

Ricky Newton describes the paper COA is releasing on patient experiences with PBMs

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Bobby Green, MD, explains how he defines big data

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Barbara McAneny, MD, discusses novel payer initiatives she finds interesting